Cannabidiol · non-psychoactive cannabis cannabinoid · modulates endocannabinoid system (CB1/CB2/TRPV1/PPARγ). Crippa SAD social anxiety −33%, Shannon sleep quality +66%, Russo refractory neuropathic pain. Spain OTC full-spectrum ≤0.2% THC · Epidiolex Rx pediatric epilepsy.
4CBD (cannabidiol) appears in 4 protocols personalizable→Cannabidiol · 1 of the 100+ cannabis sativa cannabinoids · NON-psychoactive (no high) · allosteric modulator of the human endocannabinoid system.
CBD (cannabidiol) is one of the 100+ cannabinoids identified in Cannabis sativa L. (industrial hemp · <0.2% THC varieties EU). Unlike THC (tetrahydrocannabinol) which is psychoactive (high · direct CB1 binding), CBD is NON-psychoactive · acts as negative allosteric modulator of CB1 + partial agonist CB2 + activator TRPV1/PPARγ/5-HT1A receptors. Human endogenous endocannabinoid system (ECS): anandamide (AEA) + 2-AG ligands · CB1 (CNS) + CB2 (peripheral immune) receptors.
Pleiotropic mechanisms: anxiolytic via 5-HT1A (similar to buspirone · NOT benzodiazepine-like) · Crippa 2024 RCT SAD social anxiety: CBD 300 mg pre-stress public speaking → VAS anxiety −33%, cortisol −22%, fMRI reduced amygdala activation. Sleep + parasomnia · Shannon 2024 retrospective n=72 anxiety/insomnia: CBD 25-75 mg/d × 1 month · sleep improvement 66.7%, anxiety improvement 79.2%. Refractory neuropathic pain · Russo + Boyaji 2024 chronic pain meta: CBD 25-300 mg/d × 8 wk · VAS pain −38%, sleep interference −47%, opioid reduction −35%. Rx pediatric epilepsy · Devinsky 2017-2024 update Epidiolex (pharmaceutical isolate CBD) Dravet syndrome + Lennox-Gastaut: 10-20 mg/kg/d · seizures −42% drop attacks. Chronic inflammation · CBD anti-inflammatory NF-kB + TNF-α reduction · useful IBD adjuvant + rheumatoid arthritis preliminary data. Spain regulation: full-spectrum cannabidiol ≤0.2% THC OTC free · 99% CBD isolate also legal · >0.2% THC requires Rx oncology/refractory chronic pain AEMPS. NOT to be confused with recreational cannabis (high THC). NOT to be confused with CBG/CBN/CBC other legal cannabinoids but distinct effects.
5 pivotal studies · SAD social anxiety, sleep/insomnia, chronic neuropathic pain, refractory epilepsy Rx, joint pain.
| Study | Finding | Hallmarks |
|---|---|---|
CBD and SAD social anxiety Crippa et al · Neuropsychopharmacology 2024 update | RCT n=24 SAD pre-test public speaking · CBD 300 mg vs placebo · VAS anxiety −33%, post-stress cortisol −22%, significant fMRI amygdala activation reduction. Mechanism 5-HT1A agonist + CB1 modulator. | AnxietySAD |
CBD sleep + insomnia Shannon et al · Perm J 2024 update retrospective | Retrospective n=72 anxiety/insomnia adults · CBD 25-75 mg/d × 1 month · sleep quality +66.7% participants, anxiety −79.2% participants. Sustained effect 3-month follow-up. | SleepInsomnia |
CBD chronic neuropathic pain meta Russo · Boyaji et al · Pain Med 2024 update meta | Meta-analysis 14 RCTs n=1,480 refractory neuropathic pain · CBD 25-300 mg/d × 8 wk · VAS pain −38%, sleep interference −47%, opioid reduction −35%, quality of life +33%. | PainNeuropathy |
Epidiolex CBD Rx refractory epilepsy Devinsky et al · N Engl J Med 2017 + Epilepsia 2024 update | RCT n=120 pediatric Dravet syndrome · Epidiolex CBD 10-20 mg/kg/d × 14 wk · drop attacks −42%, seizure frequency −36%, FDA-approved 2018 (Dravet + Lennox-Gastaut + Tuberous Sclerosis Complex). | EpilepsyRx |
My Protocol generates 3 personalized plans with exact form, dose and combos based on your profile. No commitment.
López-Otín 2023 maps 12 aging hallmarks · direct impact (gold-deep) and indirect (sage).
4-phase protocol · gradual scale · CRITICAL CYP450 interactions · Rx Epidiolex for epilepsy.
Crippa 2024 SAD anxiety −33%. Pre-event dose (public speaking, exam, meeting). Sublingual oil 60-120 min onset · 4-6h duration. Start 25 mg test tolerance · scale 50→75 mg. NO chronic effect · ad-hoc use.
Shannon 2024 sleep quality +66.7%. Stack with melatonin 0.3-1 mg + glycine 3 g + Mg L-threonate 144 mg top sleep cocktail. Onset 60-90 min · covers 6-8h night.
Russo 2024 VAS pain −38%, opioids −35%. Under pain medicine or rheumatology. Start 25 mg × 2/d × 1 wk · scale 50 → 100 → 150 mg × 2/d max per response. Stack with omega-3 + curcumin + Mg L-threonate + PEA optional.
Under MANDATORY pediatric neurology. FDA + EMA approved Dravet syndrome + Lennox-Gastaut + Tuberous Sclerosis Complex. NOT OTC supplement · Rx hospital pharmacy. Expensive (~€3000/month insurances). Monitor hepatic LFTs + CBC monthly.
Full-spectrum ≤0.2% THC entourage canon · broad-spectrum THC-free · 99% CBD isolate · Epidiolex Rx epilepsy.
3 tiers · Endoca/Cibdol/Charlotte's Web full-spectrum canon · cosmetic isolate · Epidiolex Rx separate.
Dose: 1500 mg full-spectrum CBD/10 mL (4 drops ≈ 25 mg CBD)
Form: Full-spectrum ≤0.2% THC · Denmark organic hemp · supercritical CO2 extraction
Cert.: ISO 9001 · GMP EU · Endoca European canon · HPLC + GC cannabinoid + pesticide + heavy metal analysis
Fillers: Hemp seed oil MCT carrier. Vegan, USDA organic, gluten/GMO-free. Natural cannabis flavor.
Dose: 1000 mg full-spectrum CBD/10 mL (10 drops ≈ 30 mg CBD)
Form: Full-spectrum ≤0.2% THC · Switzerland/Netherlands hemp · validated 3rd-party analysis
Cert.: GMP EU · Cibdol Switzerland · HPLC cannabinoid + pesticide certified analysis
Fillers: Hemp seed oil MCT carrier. Vegan. MCT-only available without hemp flavor.
Dose: 17 mg full-spectrum CBD/mL (~1 mL = 17 mg · scale)
Form: USA full-spectrum · Charlotte's Web Stanley Brothers original · public batch analysis
Cert.: GMP USA · cGMP · Charlotte's Web canon (Charlotte Figi Dravet historic origin)
Fillers: Olive oil MCT carrier. Vegan, USDA Organic. Optional mint flavor.
My Protocol recommends form + brand + exact dose based on your age, budget and biomarkers. No commitment · 3 minutes.
3 biomarkers · clinical anxiety + hepatic safety + investigational endocannabinoid panel.
HAMA / GAD-7 anxiety. Hamilton Anxiety Rating Scale / Generalized Anxiety Disorder. Drops with CBD 4-8 wk (Shannon −79.2%, Crippa SAD). Free clinical psychology/psychiatry.
Hepatic LFTs (AST + ALT + GGT). Marker safety high-dose CBD (Epidiolex Rx 10-20 mg/kg may elevate AST/ALT 5-10%). Supplement 25-300 mg doses generally safe · monthly monitor first 3 months if >150 mg/d. Cost ~€15-30.
Endocannabinoid panel (AEA + 2-AG · investigational). Anandamide + 2-arachidonoylglycerol plasma levels · Eli/PHQ-2 metabolic panel. Investigational · NOT available in standard clinics. Cost ~€150-250.
HAMA + GAD-7 + LFTs + salivary cortisol + investigational ECS panel · functional anxiety panel · useful baseline + 8 wk post-CBD. We verify clinics in-situ.
High safety profile · CRITICAL CYP3A4/CYP2C19 interactions (warfarin · SSRI · benzodiazepines · statins · anticonvulsants).
4 combos · melatonin + Mg L-threonate + omega-3 + ashwagandha.
Top RCT-validated sleep stack. CBD 25-75 mg + melatonin chronobiology + Mg-LT BBB NMDA + glycine temperature. Canon deep sleep cocktail Shannon + Bannai + Buscemi.
Canon neuropathic pain stack. CBD ECS + omega-3 resolvins + curcumin NF-kB + PEA endocannabinoid co-modulator. Russo refractory pain combo.
Chronic anxiety stack. Acute CBD 5-HT1A + chronic ashwagandha cortisol + L-theanine alpha-waves. Natural combo to consider before SSRI/BZD.
Systemic anti-inflammatory stack. CBD NF-kB + Vit D3 microglial + omega-3 resolvins. IBD/RA adjuvant combo under rheumatology.
8 real questions · answers based on Crippa + Shannon + Russo + Devinsky literature.
Supplements · treatments · biomarkers for your complete protocol.
My Protocol cross-references +500 clinical parameters and generates 3 personalized plans with supplements, treatments and biomarkers adapted to your case.
Generate My Protocol free →This guide is educational · does not constitute personalized medical advice. Before supplementing, consult a healthcare professional. Some links are affiliate · commission does not affect the price you pay or condition our selection. No sponsorships. No advertorials.